Non-Hodgkin Lymphoma

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

The FDA has approved denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The European Medicines Agency has granted orphan drug designation to SLS009 for relapsed/refractory peripheral T-cell lymphoma

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

Julie M. Vose, MD, MBA, discusses results with epcoritamab from the follicular lymphoma cycle 1 optimization cohort of the phase 1/2 EPCORE NHL-1 trial.

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Eunice Wang, MD, discusses ongoing research with menin inhibitors in patients with acute leukemias, as presented at the 2024 EHA Congress.

Soquelitinib has received fast track designation from the FDA for patients with relapsed or refractory peripheral T-cell lymphoma after at least 2 lines of systemic therapy.

Jennifer Effie Amengual, MD, of Columbia University Hebert Irving Comprehensive Cancer Center, discusses precision epigenetic targeting for germinal cancer lymphomas.

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Bexarotene has been granted marketing authorization in Hong Kong for the treatment of pretreated cutaneous manifestations of cutaneous T-cell lymphoma.

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

China’s NMPA has granted priority review to an NDA for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma.

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.

The EMA’s CHMP has recommended a conditional marketing authorization for epcoritamab for patients with relapsed/refractory follicular lymphoma.

The EMA's CHMP has recommended the conditional marketing authorization of odronextamab for relapsed/refractory FL and DLBCL.

Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.